Protagonist Therapeutics, Inc. (PTGX)

NASDAQ: PTGX · USD

$142

+0.85 (+0.6%)· Recorded snapshot

Market cap	9.2B
Revenue (ttm)	282M
Net income (ttm)	82.9M
EPS (ttm)	$1.22
Shares out	64.7M
P/E (trailing)	116.2x
P/E (forward)	66.8x
Volume	226,818
Beta	1.52

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 282M
Net income (ttm): 82.9M
EPS (ttm): $1.22
P/E (trailing): 116.2x
P/E (forward): 66.8x
Market cap: 9.2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E66.8

P25 n/aP50 n/aP75 n/a

Trailing P/E116.2

P25 n/aP50 n/aP75 n/a

ROE11

P25 n/aP50 n/aP75 n/a

ROIC61.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All PTGX indicators

Market & fundamental data

Available fields

239

Groups with data

Currency

USD

Showing 239 of 239 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001377121
Company name	Protagonist Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	74366E102
Earnings date	2026-11-09
Earnings time	amc
Employees	141
Employees change	11
Employees growth	8.46%
Enterprise value	$8.3B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2006
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2016-08-11
Is primary listing	Yes
Is SPAC	No
ISIN number	US74366E1029
Last 10-K release date	2026-02-25
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$9.2B
Market cap category	Mid-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$141.96
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	PTGX
U.S. state	California
Website	https://www.protagonist-inc.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	137.83x
Average P/E ratio (3Y)	43.75x
Earnings yield	0.86%
EV/Earnings	101.16x
EV/EBIT	143.76x
EV/EBITDA	140.06x
EV/FCF	64.23x
EV/Sales	29.74x
FCF / EV yield	1.56%
FCF yield	1.42%
Forward EV/Sales	21.46x
Forward P/E	66.83x
Forward P/S	23.61x
Graham number	18.90879
Graham upside	-86.74%
P/(FCF - SBC) ratio	114.25x
P/(OCF - SBC) ratio	113.39x
P/B ratio	10.84x
P/E ratio	116.25x
P/FCF ratio	70.66x
P/OCF ratio	70.33x
P/S ratio	32.72x
Price / tangible book value	10.96x
Price/EBITDA ratio	154.09x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	20.69%
EBITDA margin	21.24%
Effective tax rate	1.69%
FCF margin	46.31%
Gross margin	100%
Operating margin	20.69%
Pretax margin	29.91%
Profit margin	29.4%
Profit per employee	$588,007
Profitable quarters	2
Revenue per employee	$2M
ROA	4.55%
ROA (5Y)	-11.12%
ROCE	6.88%
ROE	10.98%
ROE (5Y)	-17.42%
ROIC	61.79%
SBC / revenue	17.67%
Tax / revenue	0.51%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	51.8%
EPS growth (QoQ)	4,480%
EPS growth quarters	2
EPS growth years	0
FCF growth	251.98%
Gross profit growth	34.81%
Gross profit growth (Q)	3,749.17%
Gross profit growth 5Y	59.62%
Net income growth	59.32%
Net income growth (QoQ)	4,204.76%
Net income growth quarters	2
Net income growth years	0
OCF growth	231.79%
Operating income growth	143.34%
Revenue growth	34.81%
Revenue growth (Q)	3,749.17%
Revenue growth (QoQ)	278.72%
Revenue growth 5Y	59.62%
Revenue growth quarters	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-615,000
Depreciation and amortization	$1.5M
EBIT	$58.3M
EBITDA	$59.9M
EPS	$1.22
FCF per share	$2.02
Financing cash flow	$41.6M
Free cash flow	$130.6M
Free cash flow minus SBC	$80.8M
Gross profit	$282M
Income taxes	$1.4M
Investing cash flow	$78.7M
Net cash flow	$251.5M
Net income	$82.9M
Operating cash flow minus SBC	$81.4M
Operating income	$58.3M
Revenue	$282M
Stock-based compensation	$49.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	72.22
Book value per share	$13.01
Debt / EBITDA	0.15
Debt / equity	0.01
Debt / FCF	0.07
Long-term assets	$78.4M
Long-term liabilities	$6.8M
Net cash (debt)	$840.2M
Net cash / market cap	9.11%
Net cash growth	26.99%
Net debt / EBITDA	-14.03
Net debt / equity	-1
Net debt / FCF	-6.43
Piotroski F-Score	6
Property, plant and equipment	$10.4M
Shareholders' equity	$841.5M
Tangible book value	$841.5M
Tangible book value per share	$13.01
Total assets	$885.5M
Total cash	$782.6M
Total debt	$9.2M
Total liabilities	$44M
WACC	12.62%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.35
Current assets	$807.1M
Current liabilities	$37.2M
Current ratio	21.71
Net working capital	$-10.2M
Quick ratio	21.58
Working capital	$770M
Working capital turnover	0.42

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-4.05%
Dividend yield	0%
Shareholder yield	-4.05%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	596.36%
10Y return CAGR	21.42%
10Y total return	596.36%
150-day SMA	$125.22
1D price change	0.6%
1M price change	-0.25%
1M total return	-0.25%
1W price change	2.54%
1W total return	2.54%
1Y price change	88.04%
1Y return CAGR	88.12%
1Y total return	88.04%
20-day SMA	$138.98
200-day SMA	$116.01
3M price change	4.38%
3M total return	4.38%
3Y price change	904.97%
3Y return CAGR	115.76%
3Y total return	904.97%
50-day SMA	$143.25
50-day SMA vs 200-day SMA	50over200
52-week high	$160.81
52-week high date	2026-08-19
52-week low	$74.80
52-week low date	2025-10-28
5Y price change	344.13%
5Y return CAGR	34.75%
5Y total return	344.13%
6M price change	43.64%
6M total return	43.64%
All-time high	$160.81
All-time high date	2026-08-19
All-time low	$4.47
All-time low date	2019-12-03
Average true range (ATR)	$5.47
Average volume	776.9K
Beta (1Y)	0.39
Beta (2Y)	-0.1
Beta (5Y)	1.52
Change from 52-week high	-11.72%
Change from 52-week low	89.79%
Change from all-time high	-12.01%
Change from all-time low	3,065.55%
Change from open	0.61%
Day's gap	-0.01%
Dollar volume	$32.2M
High price	$143.21
Low price	$140.94
Monthly RSI	79.94
Open price	$141.10
Position in 52-week range	44.93%
Premarket change	-0.74%
Premarket close	$141.12
Premarket price	$140.07
Premarket volume	1.5K
Previous close	$141.12
Price vs 150-day SMA	13%
Price vs 20-day SMA	1.82%
Price vs 200-day SMA	21.98%
Price vs 50-day SMA	-1.22%
Relative volume	0.29
RSI	52.77
Sharpe ratio	1.68
Sharpe ratio (3Y)	1.59
Sharpe ratio (5Y)	0.74
Sortino ratio	2.9
Sortino ratio (3Y)	3.28
Sortino ratio (5Y)	1.26
Volume	226.8K
Weekly RSI	59.6
YTD price change	62.01%
YTD total return	62.01%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	52.9M
Float percentage	81.73%
Shares change (QoQ)	0.73%
Shares change (YoY)	4.05%
Shares held by insiders	0.6%
Shares held by institutions	102.71%
Shares outstanding	64.7M
Short % of float	17.67%
Short % of shares	14.44%
Short ratio	13.6 days

Deeper analysis on PTGX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this PTGX report

Is a complete PTGX research report available?

No complete published report is available for Protagonist Therapeutics, Inc. (PTGX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Protagonist Therapeutics, Inc. (PTGX)

Price

Financial snapshot

Fair-value bridge

Latest news · PTGX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All PTGX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on PTGX

Frequently asked questions